William R Wilcox Selected Research

agalsidase beta

12/2020	Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype.
1/2018	Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.
1/2016	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
5/2015	Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
3/2012	Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
5/2007	Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
1/2007	Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William R Wilcox Research Topics

Disease

23	Fabry Disease (Fabry's Disease) 12/2020 - 02/2003
6	Achondroplasia 01/2022 - 11/2005
5	Neoplasms (Cancer) 03/2016 - 08/2007
4	Chondrosarcoma 08/2007 - 11/2005
3	Inborn Genetic Diseases (Disease, Hereditary) 05/2015 - 08/2006
3	Dwarfism 04/2015 - 07/2010
3	Multiple Myeloma 01/2014 - 06/2009
2	Diarrhea 12/2020 - 01/2018
2	Abdominal Pain (Pain, Abdominal) 12/2020 - 01/2018
2	Stroke (Strokes) 01/2016 - 05/2015
2	Proteinuria 01/2007 - 08/2003
1	Infections 12/2020
1	COVID-19 12/2020
1	X-Linked Genetic Diseases 01/2020
1	Respiratory Insufficiency (Respiratory Failure) 01/2019
1	Congenital Abnormalities (Deformity) 01/2019
1	Failure to Thrive 01/2019
1	Hypophosphatasia 01/2019
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2016
1	Hypotension (Low Blood Pressure) 12/2015
1	Schneckenbecken dysplasia 10/2015
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 05/2015
1	Renal Insufficiency (Renal Failure) 05/2015
1	Thanatophoric Dysplasia (Dwarfism, Thanatophoric) 11/2014
1	Polydactyly (Polydactylism) 08/2014
1	Triphalangeal Thumb 08/2014
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2014
1	Fibrochondrogenesis 11/2010
1	Carcinoma (Carcinomatosis) 07/2010
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 05/2010
1	Gerodermia osteodysplastica 12/2008
1	Lymphoid Leukemia 12/2007
1	Body Weight (Weight, Body) 01/2007
1	Pelger-Huet Anomaly 04/2003
1	HEM dysplasia 04/2003
1	Chronic Kidney Failure (Chronic Renal Failure) 02/2003
1	Spinocerebellar Degenerations (Marinesco Sjogren Syndrome) 05/2002

Drug/Important Bio-Agent (IBA)

8	GalactosidasesIBA 01/2020 - 03/2012
7	agalsidase beta FDA Link 12/2020 - 01/2007
7	alpha-Galactosidase (Beano)IBA 05/2010 - 02/2003
6	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 12/2021 - 06/2009
6	GlycosphingolipidsIBA 01/2018 - 08/2006
5	globotriaosylceramide (globotriosylceramide)IBA 12/2015 - 09/2005
4	EnzymesIBA 05/2015 - 09/2005
3	vosoritideIBA 01/2022 - 04/2015
3	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 01/2022 - 04/2015
3	migalastatIBA 01/2017 - 08/2016
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2012 - 07/2010
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 12/2007 - 03/2007
2	GlycolipidsIBA 12/2020 - 07/2009
2	LipidsIBA 08/2003 - 05/2002
1	AngiotensinsIBA 12/2020
1	ReninIBA 12/2020
1	CalciumIBA 01/2019
1	Pharmaceutical PreparationsIBA 03/2016
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2015
1	Inositol (Myoinositol)IBA 10/2015
1	PolyphosphatesIBA 10/2015
1	Neprilysin (Neutral Endopeptidase)IBA 04/2015
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 04/2015
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 04/2015
1	Tuberculin (PPD)IBA 08/2014
1	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 08/2014
1	Transcription Factors (Transcription Factor)IBA 01/2014
1	Phosphotransferases (Kinase)IBA 01/2014
1	Tyrosine (L-Tyrosine)FDA Link 01/2014
1	Biological ProductsIBA 01/2014
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 11/2010
1	Collagen Type XIIBA 11/2010
1	ChemokinesIBA 07/2010
1	4,4,',4'',4'''- (carbonylbis(imino- 5,1,3- benzenetriylbis(carbonylimino)))tetrakis(benzene- 1,3- disulfonate)IBA 07/2010
1	VitaminsIBA 06/2010
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 06/2009
1	Golgi Matrix ProteinsIBA 12/2008
1	Proteins (Proteins, Gene)FDA Link 12/2007
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 08/2007
1	Fibroblast Growth Factor 1 (FGF-1)IBA 03/2007
1	bisindolylmaleimide IIBA 02/2007
1	Protein Kinase CIBA 02/2007
1	Mitogen-Activated Protein KinasesIBA 11/2005
1	Natriuretic PeptidesIBA 11/2005
1	CreatinineIBA 08/2003
1	ChromatinIBA 04/2003
1	delta(14)-sterol reductaseIBA 04/2003
1	Lamin B ReceptorIBA 04/2003

Therapy/Procedure

11	Therapeutics 12/2020 - 02/2003
10	Enzyme Replacement Therapy 12/2020 - 02/2003
1	Mechanical Ventilators (Ventilator) 01/2019
1	Precision Medicine 03/2016
1	Renal Dialysis (Hemodialysis) 01/2016
1	Heart Transplantation (Grafting, Heart) 01/2016
1	Intravenous Infusions 01/2007